Journal Article Review Research Support, Non-U.S. Gov't Ppublish 15 citations
PubMed: 38164737 DOI: 10.20892/j.issn.2095-3941.2023.0381
Bronchoalveolar lavage fluid assessment facilitates precision medicine for lung cancer.
Cancer Biol Med 21(3)
Authors: Hantao Zhang, Dan Deng, Shujun Li, Jing Ren, Wei Huang, Dan Liu, Weiya Wang
Affiliations
- Department of Pathology, West China Hospital, Sichuan University, Chengdu 610000, China. West China Biobank, West China Hospital, Sichuan University, Chengdu 610000, China.
- West China Biobank, West China Hospital, Sichuan University, Chengdu 610000, China.
- Department of Respiratory and Critical Care Medicine, Clinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu 610000, China.
- Department of Pathology, West China Hospital, Sichuan University, Chengdu 610000, China.
Abstract
Lung cancer is the most common and fatal malignant disease worldwide and has the highest mortality rate among tumor-related causes of death. Early diagnosis and precision medicine can significantly improve the survival rate and prognosis of lung cancer patients. At present, the clinical diagnosis of lung cancer is challenging due to a lack of effective non-invasive detection methods and biomarkers, and treatment is primarily hindered by drug resistance and high tumor heterogeneity. Liquid biopsy is a method for detecting circulating biomarkers in the blood and other body fluids containing genetic information from primary tumor tissues. Bronchoalveolar lavage fluid (BALF) is a potential liquid biopsy medium that is rich in a variety of bioactive substances and cell components. BALF contains information on the key characteristics of tumors, including the tumor subtype, gene mutation type, and tumor environment, thus BALF may be used as a diagnostic supplement to lung biopsy. In this review, the current research on BALF in the diagnosis, treatment, and prognosis of lung cancer is summarized. The advantages and disadvantages of different components of BALF, including cells, cell-free DNA, extracellular vesicles, and microRNA are introduced. In particular, the great potential of extracellular vesicles in precision diagnosis and detection of drug-resistant for lung cancer is highlighted. In addition, the performance of liquid biopsies with different body fluid sources in lung cancer detection are compared to facilitate more selective studies involving BALF, thereby promoting the application of BALF for precision medicine in lung cancer patients in the future.
MeSH
Diagnosis, Prognosis, Cells, Lung Neoplasms, Precision Medicine, Genes, Bronchoalveolar Lavage Fluid, Liquid Biopsy
Cited by
- Integrated multi-omics landscape of non-small cell lung cancer with distant metastasis. Front Immunol, 2025
- Advancements in diagnosis and treatment of lung adenocarcinoma patients under ECMO support: a case series and comprehensive literature review. J Cardiothorac Surg, 2025
- Innovative diagnostic approaches for lung cancer: integrating traditional cytology with qPCR for rapid and reliable results. Sci Rep, 2025
- Comparative Brain and Serum Exosome Expression of Biomarkers in an Experimental Model of Alzheimer-Type Neurodegeneration: Potential Relevance to Liquid Biopsy Diagnostics. Int J Mol Sci, 2025
- Aggregation-Induced Emission Luminogen: Role in Biopsy for Precision Medicine. Chem Rev, 2024
- Bacterial Extracellular Vesicles in Oncology: Molecular Mechanisms and Future Clinical Applications. Cancers (Basel), 2025
- Single-cell transcriptome sequencing reveals the immune microenvironment in bronchoalveolar lavage fluid of checkpoint inhibitor-related pneumonitis. Cancer Immunol Immunother, 2025